Macrophage polarization: the epigenetic point of view

Current Opinion in Lipidology

Volumn 25, Issue 5, 2014, Pages 367-373

  Van Den Bossche, Jan ^a   Neele, Annette E ^a   Hoeksema, Marten A ^a   De Winther, Menno P J ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

Enhancers; Epigenetics; Histone modifications; Histone modifying enzymes; Macrophage polarization

Indexed keywords

BINDING PROTEIN; HISTONE DEACETYLASE 3; JUMONJI DOMAIN CONTAINING PROTEIN 3; UNCLASSIFIED DRUG; HISTONE DEACETYLASE; HISTONE DEMETHYLASE; KDM6B PROTEIN, HUMAN;

ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL METABOLISM; ENHANCER REGION; EPIGENETICS; HUMAN; MACROPHAGE; MACROPHAGE ACTIVATION; NONHUMAN; PHENOTYPE; POLARIZATION; PRIORITY JOURNAL; PROMOTER REGION; REVIEW; CELL POLARITY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; METABOLISM; PATHOLOGY; PHAGOCYTOSIS;

ATHEROSCLEROSIS; CELL DIFFERENTIATION; CELL POLARITY; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; HISTONE DEACETYLASES; HUMANS; JUMONJI DOMAIN-CONTAINING HISTONE DEMETHYLASES; MACROPHAGE ACTIVATION; MACROPHAGES; PHAGOCYTOSIS;

EID: 84914095427     PISSN: 09579672     EISSN: 14736535     Source Type: Journal    
DOI: 10.1097/MOL.0000000000000109     Document Type: Review

References (51)

1. Hoeksema MA, Stoger JL, de Winther MP. Molecular pathways regulating macrophage polarization: Implications for atherosclerosis. Curr Atheroscler Rep 2012; 14: 254-263.
2. Wolfs IM, Stoger JL, Goossens P, et al. Reprogramming macrophages to an anti-inflammatory phenotype by helminth antigens reduces murine atherosclerosis. FASEB J 2014; 28: 288-299.
3. Locati M, Mantovani A, Sica A. Macrophage activation and polarization as an adaptive component of innate immunity. Adv Immunol 2013; 120: 163-184.
4. Van den Bossche J, Bogaert P, van Hengel J, et al. Alternatively activated macrophages engage in homotypic and heterotypic interactions through IL-4 and polyamine-induced E-cadherin/catenin complexes. Blood 2009; 114: 4664-4674.
5. Van den Bossche J, LamersWH,Koehler ES, et al. Pivotal advance: Arginase-1- independent polyamine production stimulates the expression of IL-4-induced alternatively activated macrophage markers while inhibiting LPS-induced expression of inflammatory genes. J Leukoc Biol 2012; 91: 685-699.
6. Martinez FO, Helming L, Milde R, et al. Genetic programs expressed in resting and IL-4 alternatively activated mouse and human macrophages: Similarities and differences. Blood 2013; 121: E57-e69.
7. Stender JD, Glass CK. Epigenomic control of the innate immune response. Curr Opin Pharmacol 2013; 13: 582-587.
8. Ghisletti S, Natoli G. Deciphering cis-regulatory control in inflammatory cells. Philos Trans R Soc Lond B Biol Sci 2013; 368: 20120370.
9. Ghisletti S, Barozzi I, Mietton F, et al. Identification and characterization of enhancers controlling the inflammatory gene expression program in macrophages. Immunity 2010; 32: 317-328.
10. Natoli G. Specialized chromatin patterns in the control of inflammatory gene expression. Curr Top Microbiol Immunol 2011; 349: 61-72.
11. Heinz S, Benner C, Spann N, et al. Simple combinations of lineage-determining transcription factors prime cis-regulatory elements required for macrophage and B cell identities. Mol Cell 2010; 38: 576-589.
12. Heinz S, Romanoski CE, Benner C, et al. Effect of natural genetic variation on enhancer selection and function. Nature 2013; 503: 487-492.
13. Kaikkonen MU, Spann NJ, Heinz S, et al. Remodeling of the enhancer landscape during macrophage activation is coupled to enhancer transcription. Mol Cell 2013; 51: 310-325.
14. Ostuni R, Piccolo V, Barozzi I, et al. Latent enhancers activated by stimulation in differentiated cells. Cell 2013; 152: 157-171.
15. Simonatto M, Natoli G. Functional genomics of the inflammatory response: Where are we now? Brief Funct Genomics 2013; 12: 483-488.
16. Heintzman ND, Stuart RK, Hon G, et al. Distinct and predictive chromatin signatures of transcriptional promoters and enhancers in the human genome. Nat Genet 2007; 39: 311-318.
17. Heintzman ND, Hon GC, Hawkins RD, et al. Histone modifications at human enhancers reflect global cell-type-specific gene expression. Nature 2009; 459: 108-112.
18. Creyghton MP, Cheng AW, Welstead GG, et al. Histone H3K27ac separates active from poised enhancers and predicts developmental state. Proc Natl Acad Sci U S A 2010; 107: 21931-21936.
19. Rada-Iglesias A, Bajpai R, Swigut T, et al. A unique chromatin signature uncovers early developmental enhancers in humans. Nature 2011; 470: 279-283.
20. Wang Z, Zang C, Rosenfeld JA, et al. Combinatorial patterns of histone acetylations and methylations in the human genome. Nat Genet 2008; 40: 897-903.
21. Kittan NA, Allen RM, Dhaliwal A, et al. Cytokine induced phenotypic and epigenetic signatures are key to establishing specific macrophage phenotypes. PLoS One 2013; 8: E78045.
22. Stender JD, Pascual G, Liu W, et al. Control of proinflammatory gene programs by regulated trimethylation and demethylation of histone H4K20. Mol Cell 2012; 48: 28-38.
23. De Santa F, Totaro MG, Prosperini E, et al. The histone H3 lysine-27 demethylase Jmjd3 links inflammation to inhibition of polycomb-mediated gene silencing. Cell 2007; 130: 1083-1094.
24. De Santa F, Narang V, Yap ZH, et al. Jmjd3 contributes to the control of gene expression in LPS-activated macrophages. EMBO J 2009; 28: 3341-3352.
25. Yan Q, Sun L, Zhu Z, et al. Jmjd3-mediated epigenetic regulation of inflammatory cytokine gene expression in serum amyloid A-stimulated macrophages. Cell Signal 2014; 26: 1783-1791.
26. Kruidenier L, Chung CW, Cheng Z, et al. A selective jumonji H3K27 demethylase inhibitor modulates the proinflammatory macrophage response. Nature 2012; 488: 404-408.
27. Ishii M, Wen H, Corsa CA, et al. Epigenetic regulation of the alternatively activated macrophage phenotype. Blood 2009; 114: 3244-3254.
28. Satoh T, Takeuchi O, Vandenbon A, et al. The Jmjd3-Irf4 axis regulates M2 macrophage polarization and host responses against helminth infection. Nat Immunol 2010; 11: 936-944.
29. Yasui T, Hirose J, Tsutsumi S, et al. Epigenetic regulation of osteoclast differentiation: Possible involvement of Jmjd3 in the histone demethylation of Nfatc1. J Bone Miner Res 2011; 26: 2665-2671.
30. Chen S, Ma J, Wu F, et al. The histone H3 Lys 27 demethylase JMJD3 regulates gene expression by impacting transcriptional elongation. Genes Dev 2012; 26: 1364-1375.
31. Mullican SE, Gaddis CA, Alenghat T, et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2011; 25: 2480-2488.
32. Chen X, Barozzi I, Termanini A, et al. Requirement for the histone deacetylase Hdac3 for the inflammatory gene expression program in macrophages. Proc Natl Acad Sci U S A 2012; 109: E2865-E2874.
33. Roger T, Lugrin J, Le RD, et al. Histone deacetylase inhibitors impair innate immune responses to Toll-like receptor agonists and to infection. Blood 2011; 117: 1205-1217.
34. Serrat N, Sebastian C, Pereira-Lopes S, et al. The response of secondary genes to lipopolysaccharides in macrophages depends on histone deacetylase and phosphorylation of CCAAT(cytosine-cytosine-adenosine-adenosinethymidine)/ enhancer binding protein beta. J Immunol 2014; 192: 418-426.
35. ShakespearMR, Halili MA, Irvine KM, et al. Histone deacetylases as regulators of inflammation and immunity. Trends Immunol 2011; 32: 335-343.
36. Jeong Y, Du R, Zhu X, et al. Histone deacetylase isoforms regulate innate immune responses by deacetylating mitogen-activated protein kinase phosphatase- 1. J Leukoc Biol 2014; 95: 651-659.
37. Kong S, Yeung P, Fang D. The class III histone deacetylase sirtuin 1 in immune suppression and its therapeutic potential in rheumatoid arthritis. J Genet Genomics 2013; 40: 347-354.
38. Stein S, Matter CM. Protective roles of SIRT1 in atherosclerosis. Cell Cycle 2011; 10: 640-647.
39. Belkina AC, Nikolajczyk BS, Denis GV. BET protein function is required for inflammation: Brd2 genetic disruption and BET inhibitor JQ1 impair mouse macrophage inflammatory responses. J Immunol 2013; 190: 3670-3678.
40. Nicodeme E, Jeffrey KL, Schaefer U, et al. Suppression of inflammation by a synthetic histone mimic. Nature 2010; 468: 1119-1123.
41. Nguyen KD, Fentress SJ, Qiu Y, et al. Circadian gene Bmal1 regulates diurnal oscillations of Ly6C(hi) inflammatory monocytes. Science 2013; 341: 1483-1488.
42. Tumes DJ, Onodera A, Suzuki A, et al. The polycomb protein Ezh2 regulates differentiation and plasticity of CD4(+) T helper type 1 and type 2 cells. Immunity 2013; 39: 819-832.
43. Mullican SE, Gaddis CA, Alenghat T, et al. Histone deacetylase 3 is an epigenomic brake in macrophage alternative activation. Genes Dev 2011; 25: 2480-2488.
44. Kaelin WG Jr, McKnight SL. Influence of metabolism on epigenetics and disease. Cell 2013; 153: 56-69.
45. Pearce EL, Pearce EJ. Metabolic pathways in immune cell activation and quiescence. Immunity 2013; 38: 633-643.
46. Tannahill GM, Curtis AM, Adamik J, et al. Succinate is an inflammatory signal that induces IL-1beta through HIF-1alpha. Nature 2013; 496: 238-242.
47. Vats D,Mukundan L, Odegaard JI, et al. Oxidative metabolism and PGC-1beta attenuate macrophage-mediated inflammation. Cell Metab 2006; 4: 13-24.
48. O'Neill LA, Hardie DG. Metabolism of inflammation limited by AMPK and pseudo-starvation. Nature 2013; 493: 346-355.
49. Mounier R, Theret M, Arnold L, et al. AMPKalpha1 regulates macrophage skewing at the time of resolution of inflammation during skeletal muscle regeneration. Cell Metab 2013; 18: 251-264.
50. Marazzi I, Ho JS, Kim J, et al. Suppression of the antiviral response by an influenza histone mimic. Nature 2012; 483: 428-433.
51. Hawkins RD, Larjo A, Tripathi SK, et al. Global chromatin state analysis reveals lineage-specific enhancers during the initiation of human T helper 1 and T helper 2 cell polarization. Immunity 2013; 38: 1271-1284.